Anti-TNF therapy: Where have we got to in 2005?

被引：75

作者：

Feldmann, M ^{[1
]}

Brennan, FM ^{[1
]}

Foxwell, BMJ ^{[1
]}

Taylor, PC ^{[1
]}

Williams, RO ^{[1
]}

Maini, RN ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England

来源：

JOURNAL OF AUTOIMMUNITY | 2005年 / 25卷

基金：

英国惠康基金;

关键词：

anti-TNF;

D O I：

10.1016/j.jaut.2005.09.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

The blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to augmented therapeutic benefit. There are still many limitations, but the prospects for the future are intriguing. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：26 / 28

页数：3

共 29 条

[1]

ASKLING J, 2005, ANN RHEUM DIS

[2]

PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN [J].